• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sinovac Shareholders Vote to Remove Current Directors and Elect SAIF Partners Nominees to Board at Special Meeting

    7/9/25 1:17:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care
    Get the next $SVA alert in real time by email

    Shareholders Voted to Approve Both SAIF Partners Proposals at Special Meeting

    Newly Elected Directors Are Committed to Support and Execute the Announced Payout of Dividends and Unlock Sinovac's Long-Term Value for All Shareholders Through the Resumption of Trading of Sinovac's Common Shares

    SAIF Partners IV L.P., ("SAIF Partners", "we" or "us"), today announced that Sinovac Biotech Ltd. ("Sinovac" or the "Company") shareholders voted to approve SAIF Partners' proposals to remove the Company's incumbent directors and to elect SAIF Partners' slate of ten highly qualified director nominees to the Board of Directors (the "Board") at Sinovac's Special Meeting of Shareholders (the "Special Meeting").

    On July 8, 2025, at 8:00 p.m. Atlantic Standard Time, Sinovac's incumbent Chairman Chiang Li convened, then immediately purported to adjourn, the Special Meeting without allowing shareholders to participate. SAIF Partners representatives, alongside those of other shareholders, had arrived at the Special Meeting intending to participate in the meeting.

    Subsequently, the shareholder representatives present convened a continuation of the Special Meeting, chaired by incumbent Sinovac Director Mr. Yuk Lam Lo, the only remaining director on the incumbent Board approved by Privy Council. During the Special Meeting, Sinovac's shareholders voted to approve both of SAIF Partners' proposals, based on a tabulation of votes cast on SAIF Partners' gold proxy card and the Company's white proxy card.

    The newly elected directors of the Company are committed to supporting and executing Sinovac's announced payout of dividends and working closely with Sinovac's management to unlock long-term value for all shareholders by pursuing the resumption of trading of the Company's common shares to help Sinovac realize its tremendous potential.

    About SAIF Partners

    SAIF Partners is a leading Asian private equity firm with cumulative assets under management of over $4 billion. SAIF Partners is an active lead investor working closely with its portfolio companies to develop their business both organically and through acquisitions, seeking synergistic cooperation among them, as well as enhancing shareholder value via promotion of good corporate governance and best management practices.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250708978710/en/

    Media Contacts

    Jonathan Gasthalter/Mark Semer/Grace Cartwright

    Gasthalter & Co.

    +1 (212) 257 4170

    [email protected]

    Investor Contacts

    Paul Schulman/Bill Dooley/Jon Eyl

    Sodali & Co.

    + 1 (203) 658-9400

    [email protected]

    Get the next $SVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SVA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    /C O R R E C T I O N -- Heng Ren Partners/

    In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issued Nov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared b

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment

    BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared by the board. Sinovac's stock has been halted from trading since 2019. As a result, Sinovac shareholders missed out on an extraordinary windfall from the success of its COVID-19 vaccine, CoronaVac, and its billions of dollars in sales during the pandemic due to the trading halt. In July 2025, the current Board paid a $55.00 dividend to shareholders as partial compensation for dividends that h

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Announces Appointment of Independent Auditor

    Critical step in improving transparency and resuming trading on NASDAQ The Board of Directors and Management of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Audit Committee of the Board has approved the engagement of UHY LLP ("UHY") headquartered in the U.S. as its independent auditor and registered public accounting firm, effective today, October 24, 2025. UHY is a U.S. member of Urbach Hacker Young International Limited (UHY International), a UK company, and forms part of the international UHY network of legally independent accounting and consulting firms. As a matter of priority, UH

    10/24/25 10:30:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    SEC Filings

    View All

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/10/25 9:54:16 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/9/25 9:53:38 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/9/25 9:55:18 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Leadership Updates

    Live Leadership Updates

    View All

    SINOVAC Announces Appointment of Independent Auditor

    Critical step in improving transparency and resuming trading on NASDAQ The Board of Directors and Management of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Audit Committee of the Board has approved the engagement of UHY LLP ("UHY") headquartered in the U.S. as its independent auditor and registered public accounting firm, effective today, October 24, 2025. UHY is a U.S. member of Urbach Hacker Young International Limited (UHY International), a UK company, and forms part of the international UHY network of legally independent accounting and consulting firms. As a matter of priority, UH

    10/24/25 10:30:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders

    Special Meeting validly adjourned until the appropriate court makes a final decision on validity of the PIPE shares and will be reconvened SAIF and the Dissenting Investor Group's deceptive claims of a "continuation of the Special Meeting" and a pretend "Board" are fake and without legal basis Current Board remains the only valid board of directors of SINOVAC and will continue to govern the Company The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company") today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the "Special Meeting"): The Special Meeting was validly adjourned by SINOVAC Chairman Chian

    7/11/25 4:21:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC

    Court denies Vivo Capital's petition for relief relating to shareholder votes and corporate governance, clearing another legal hurdle for distribution of the US$55.00 per common share special cash dividend Marks fourth unsuccessful legal attempt in deceptive and disparaging campaign by Advantech/Prime or Vivo Capital against current Board and its Chairman New reports from two leading independent proxy advisory firms, Glass Lewis and ISS, firmly recommend shareholders vote to KEEP the current Board chaired by Dr. Chiang Li The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced

    7/7/25 1:46:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Financials

    Live finance-specific insights

    View All

    /C O R R E C T I O N -- Heng Ren Partners/

    In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issued Nov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared b

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Newly Elected Directors of Sinovac Hold the First Board Meeting

    Mr. Andrew Y. Yan elected Chairman of the Board New Board Unanimously Resolved to Explore Future Dividend Plans, Conduct Search for New Auditor for Resuming NASDAQ Trading, and Restore Stable Operations of the Company, Amongst Other Things Sinovac Biotech Ltd. (NASDAQ:SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the new Directors), held its first meeting today at the Company's headquar

    7/10/25 7:23:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment

    Special cash dividend is being paid to valid common shareholders who owned SINOVAC as of the close of business on July 7, 2025 Board will continue to prioritize dividend distributions according to its previously announced policy For any questions about the dividend payment process, shareholders should contact Dividend Information Agent D.F. King at [email protected] The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the previously declared US$55.00 per common share special cash dividend is in the process of being paid to valid shareholders who owned SINOVAC shares as of

    7/9/25 12:27:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

    SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    9/12/24 4:03:46 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

    SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    6/17/24 4:02:44 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Sinovac Biotech, Ltd. (Amendment)

    SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    3/20/24 7:33:23 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care